Figure 1316

A recent meta-analysis of published trials in renal transplant recipients demonstrated these benefits of the various treatments. Pharmacologic therapy should be instituted at low doses with cautious surveillance for potential adverse effects, especially liver dysfunction or rhabdomyolysis. These adverse events may occur more frequently in transplant recipients owing to the effect of cyclosporine on drug disposition. Levels of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors are substantially higher in patients receiving both drugs [27]. HDL—high density lipoprotein; LDL—low density lipoprotein. (Adapted from Massy and coworkers [27]; with permission.)

0 0

Post a comment